87674-21-3

Basic information

• Product Name: Ethanone, 1-(3-fluoro-4-pyridinyl)- (9CI)
• Synonyms: Ethanone, 1-(3-fluoro-4-pyridinyl)- (9CI);1-(3-Fluoro-4-pyridinyl)ethanone;3-Fluoro-4-acetylpyridine;4-Acetyl-3-fluoropyridine;Ethanone, 1-(3-fluoro-4-pyridinyl)-
• CAS NO: 87674-21-3
• Molecular Formula: C7H6FNO
• Molecular Weight: 139.1270432
• Product Categories: ACETYLGROUP
• Mol File: 87674-21-3.mol

Chemical Properties

• Boiling Point: 199℃
• Flash Point: 74℃
• Appearance: /
• Density: 1.175
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.10±0.18(Predicted)
• CAS DataBase Reference: Ethanone, 1-(3-fluoro-4-pyridinyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(3-fluoro-4-pyridinyl)- (9CI)(87674-21-3)
• EPA Substance Registry System: Ethanone, 1-(3-fluoro-4-pyridinyl)- (9CI)(87674-21-3)

Safety Data

• Hazardous Substances Data: 87674-21-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethanone, 1-(3-fluoro-4-pyridinyl)(9CI) is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with improved therapeutic properties and reduced side effects. Ethanone, 1-(3-fluoro-4-pyridinyl)(9CI)'s versatility in chemical reactions enables the creation of a wide range of drug candidates for the treatment of various diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical industry, Ethanone, 1-(3-fluoro-4-pyridinyl)(9CI) is utilized as a building block for the synthesis of novel agrochemical products. Its incorporation into the molecular structure of these products can enhance their effectiveness in controlling pests, diseases, and weeds, while minimizing the environmental impact. Ethanone, 1-(3-fluoro-4-pyridinyl)(9CI)'s potential applications in this field contribute to the development of more sustainable and efficient agricultural practices.
Used in Research and Development:
Ethanone, 1-(3-fluoro-4-pyridinyl)(9CI) is also employed in research and development laboratories for the exploration of new chemical reactions and the synthesis of innovative compounds. Its unique properties and reactivity make it a valuable tool for chemists working on the design and synthesis of new molecules with potential applications in various fields, including materials science, nanotechnology, and environmental science.

Upstream product

• 393-53-3 3-fluoroisonicotinic acid 
• 372-47-4 3-Fluoropyridine 
• 78191-00-1 N-Methoxy-N-methylacetamide 
• 1187669-49-3 3-fluoro-N-methyl-N-(methyloxy)-4-pyridinecarboxamide 
• 75-16-1 methylmagnesium bromide 
• 87674-15-5 4-(1-hydroxyethyl)-3-fluoropyridine 

Downstream Products

• 1187669-48-2 4-(3-fluoro-4-pyridinyl)-N-(3-methylphenyl)-1,3-thiazol-2-amine 

Relevant articles and documents

NOVEL GPR119 AGONIST COMPOUNDS

The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.

PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF

Disclosed herein are pyridine derivatives, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, pharmaceutical compositions comprising the same, and methods of modulating the level or activity of HIF in a subject, inhibiting hydroxylation of HIFα in a subject, modulating expression of HIF-regulated genes in a subject, treating an HIF-related disorder in a subject, increasing levels of endogenous EPO in a subject, or treating a disorder in a subject, using the disclosed compounds.

2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles

A novel series of AKT inhibitors containing 2,3,5-trisubstituted pyridines with novel azaindazoles as hinge binding elements are described. Among these, the 4,7-diazaindazole compound 2c has improved drug-like properties and kinase selectivity than those of indazole 1, and displays greater than 80% inhibition of GSK3β phosphorylation in a BT474 tumor xenograft model in mice.

4-Pyridylanilinothiazoles that selectively target von Hippel - Lindau deficient renal cell carcinoma cells by inducing autophagic cell death

Renal cell carcinomas (RCC) are refractory to standard therapy with advanced RCC having a poor prognosis; consequently treatment of advanced RCC represents an unmet clinical need. The von Hippel-Lindau (VHL) tumor suppressor gene is mutated or inactivated in a majority of RCCs. We recently identified a 4-pyridyl-2-anilinothiazole (PAT) with selective cytotoxicity against VHL-deficient renal cells mediated by induction of autophagy and increased acidification of autolysosomes. We report exploration of structure-activity relationships (SAR) around this PAT lead. Analogues with substituents on each of the three rings, and various linkers between rings, were synthesized and tested in vitro using paired RCC4 cell lines. A contour map describing the relative spatial contributions of different chemical features to potency illustrates a region, adjacent to the pyridyl ring, with potential for further development. Examples probing this domain validated this approach and may provide the opportunity to develop this novel chemotype as a targeted approach to the treatment of RCC. 2009 American Chemical Society.

HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT

Provided herein are novel heteroaryl compounds, compositions comprising the compounds, and methods of treatment or prevention comprising administration of the compounds. The compounds are effective in the targeting of cells defective in the von Hippel-Lindau gene and in inducing autophagic cell death. The methods are directed to treating or preventing diseases such as cancer, and in particular cancers resulting from von Hippel-Lindau disease. The compounds of the invention may be administered in combination with another therapeutic agent.

Heteroarylpyrrolopyridinones active as kinase inhibitors

Compounds represented by formula (I) wherein A, R1, R2, R3, R4, R5 and R6 are as defined in the specification or a pharmaceutically acceptable salt or solvate thereof, compositions thereof,

N-substituted pyrrolopyridinones active as kinase inhibitors

Compounds represented by formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

PYRROLOPYRROLONES ACTIVE AS KINASE INHIBITORS

Compounds represented by formula (I) wherein A, R1, R2, R3, and R4 are as defined in the specification, compositions thereof, and methods of use thereof.

PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS

Pyridylpyrrole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treat

REVIEW ON THE METALLATION OF ?-DEFICIENT HETEROAROMATIC COMPOUNDS; REGIOSELECTIVE ORTHO-LITHIATION OF 3-FLUOROPYRIDINE: DIRECTING EFFECTS AND APPLICATION TO SYNTHESIS OF 2,3- OR 3,4-DISUBSTITUTED PYRIDINES

Metallation of ?-deficient heterocyclic compounds is first reviewed, which shows the important recent developments in this research area.A particular aspect of this reaction is then given with the study of the 3-fluoropyridine metallation regioselectivity.Lithiation of 3-fluoropyridine is chemoselective at low temperatures using butyllithium-polyamine chelates or lithium diisopropylamide.Protophilic attack by these strong bases can be directed either at the 2- or 4-position depending on the lithiation conditions.Various reaction parameters are thus studied such as solvent, temperature, reaction time, lithium-chelating agent as well as metallating agent.The high regioselectivity of 3-fluoropyridine lithiation is theoretically discused, in particular in terms of kinetic of thermodynamic control of the metallation.Chelation between butyllithium and 3-fluoropyridine is proposed, which completely modifies the heterocycle reactivity toward the lithiating agent.This is confirmed by theoretical quantum calculations performed on different models of 3-fluoropyridine using the CNDO/2.These results allow to select the best 3-fluoropyridine-metallation conditions which lead to 3-fluoro-2-lithiopyridine on the one hand and to 3-fluoro-4-lithiopyridine on the other hand.Each of the lithiated isomers is then reacted with a great variety of electrophiles which gives very conveniently the corresponding 2,3- or 3,4-disubstituted pyridines.